Banyan provides TBI biomarkers to Abbott

Create PDF

June 2019—Banyan Biomarkers will provide Abbott a license for its traumatic brain injury blood biomarkers, ubiquitin carboxy-terminal hydrolase-L1 (UCH-L1) and glial fibrillary acidic protein (GFAP), for use on Abbott’s core laboratory instruments. Abbott is developing a TBI assessment blood test for the point of care and its core laboratory instruments.